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Abstract
Background: Activating mutations in KRAS are prevalent in lung cancer and have been causally linked to the
oncogenic process. However, therapies targeted to oncogenic RAS have been ineffective to date and identification
of KRAS targets that impinge on the oncogenic phenotype is warranted. Based on published studies showing that
mitotic kinases Aurora A (AURKA) and B (AURKB) cooperate with oncogenic RAS to promote malignant
transformation and that AURKA phosphorylates RAS effector pathway components, the aim of this study was to
investigate whether AURKA and AURKB are KRAS targets in lung cancer and whether targeting these kinases might
be therapeutically beneficial.
Methods: In order to determine whether oncogenic KRAS induces Aurora kinase expression, we used qPCR and
western blotting in three different lung cell-based models of gain- or loss-of-function of KRAS. In order to
determine the functional role of these kinases in KRAS-induced transformation, we generated KRAS-positive A549
and H358 cells with stable and inducible shRNA-mediated knockdown of AURKA or AURKB and evaluated
transformation in vitro and tumor growth in vivo. In order to validate AURKA and/or AURKB as therapeutically
relevant KRAS targets in lung cancer, we treated A549 and H358 cells, as well as two different lung cell based
models of gain-of-function of KRAS with a dual Aurora kinase inhibitor and performed functional in vitro assays.
Results: We determined that KRAS positively regulates AURKA and AURKB expression. Furthermore, in KRAS-positive
H358 and A549 cell lines, inducible knockdown of AURKA or AURKB, as well as treatment with a dual AURKA/AURKB
inhibitor, decreased growth, viability, proliferation, transformation, and induced apoptosis in vitro. In addition,
inducible shRNA-mediated knockdown of AURKA in A549 cells decreased tumor growth in vivo. More importantly,
dual pharmacological inhibiton of AURKA and AURKB reduced growth, viability, transformation, and induced
apoptosis in vitro in an oncogenic KRAS-dependent manner, indicating that Aurora kinase inhibition therapy can
specifically target KRAS-transformed cells.
Conclusions: Our results support our hypothesis that Aurora kinases are important KRAS targets in lung cancer and
suggest Aurora kinase inhibition as a novel approach for KRAS-induced lung cancer therapy.
Background
Activation of KRAS by mutation is a very common event
in human malignancies. In spite of intensive investigation,
KRAS-related malignancies currently lack effective ther-
apies. Direct targeting of KRAS by blocking its post-
translational prenylation has failed in clinical trials [1].
Targeting KRAS downstream effectors has also been
challenging, as KRAS regulates a multitude of effectors
that contribute to the oncogenic phenotype [2, 3]. It is
likely that successful KRAS targeting will involve com-
bined inhibition of specific key targets. Considering that
targeting traditional KRAS effectors has so far had limited
success [1, 4], the identification of novel KRAS targets that
impinge on the oncogenic phenotype is warranted in
order to increase the possibilities of combinatorial therapy
design and achieve therapeutic efficacy.
Achieving therapeutic efficacy is particularly important
in lung cancer, which is the leading cause of cancer-
related deaths [5]. Even though effective targeted therapies
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have been developed for lung cancer, these therapies bene-
fit a small percentage of patients because they target onco-
genic events that are infrequent in lung cancer [6, 7].
KRAS mutations, however, are very common in lung can-
cer ranging from 30–50 % of patients and are associated
with poor prognosis and therapy resistance [8, 9]. None-
theless, effective targeted therapy options for lung cancer
patients with KRAS mutations are currently lacking.
Aurora kinases A and B belong to a new family of
serine/threonine kinases, which are essential regulators of
mitosis [10, 11] and have been recently implicated in
DNA repair [12, 13]. They are also overexpressed in a
number of human cancers [14, 15], including lung cancers
[16–19]. In addition, both kinases have been implicated in
promoting oncogenesis [20–25]. Aurora A expression can
transform cells and induce tumor formation in mice [24,
26] and Aurora B overexpression promotes lung carcino-
genesis and increased invasiveness in vivo [25]. In
addition, these kinases have been shown to promote gen-
etic instability leading to aneuploidy [21, 26–29] and to
block p53 function, thereby preventing cell apoptosis [30,
31]. Finally, these kinases have been shown to cooperate
with RAS to induce malignant transformation [28, 32–37].
Even though these kinases are being investigated as thera-
peutic targets, and specific Aurora kinase inhibitors have
been developed and are undergoing clinical trials for dif-
ferent malignancies [14, 15, 38], it is not known whether
these kinases are KRAS targets in lung oncogenesis, or if
targeting these kinases could lead to a therapeutic benefit
for lung cancer patients harboring KRAS mutations.
In this study we investigated Aurora A and Aurora B as
potential KRAS targets in lung cancer. We show, not only
that, in lung cells, KRAS regulates Aurora A and B expres-
sion, but also that targeting these kinases in lung cells by
different approaches reduces cell growth, proliferation and
anchorage-independent growth, while at the same time it
induces apoptosis. Interestingly, these effects were more
pronounced in the presence of oncogenic KRASG12V, and
Aurora inhibition had no effect on normal or tumorigenic
cells without KRAS mutations. This suggests that Aurora
kinase inhibition therapy can specifically target KRAS
transformed cells. Finally, AURKA inhibition by RNA inter-
ference reduced lung tumor xenograft growth in vivo. In
conclusion, our results support our hypothesis that Aurora
kinases are important KRAS targets in lung cancer and sug-
gest Aurora kinase inhibition as a novel and specific ap-
proach to be explored for KRAS-induced lung cancer
therapy.
Results
Oncogenic KRAS induces Aurora A and Aurora B
expression
Because both AURKA and AURKB can cooperate with
RAS to promote malignant transformation [28, 32–37],
and because AURKA can activate the RAS downstream
effector RalA [39], we hypothesized that KRAS could pro-
mote Aurora kinase expression, as part of its oncogenic
activity. In order to determine whether oncogenic KRAS
regulates expression of AURKA or AURKB, we used three
cell-based models. Initially, we used an isogenic pair
consisting of immortalized primary pulmonary cells trans-
formed or not with oncogenic KRAS [40]. KRAS-
transformed SAKRAS cells express higher levels of RAS
proteins in comparison with their non-transformed
SALEB counterparts, as expected. Interestingly, SAKRAS
cells also express higher levels of AURKA and AURKB
(Fig. 1a). In order to determine if these increased Aurora
kinase levels could reflect increased AURKA and AURKB
transcription in SAKRAS cells, we performed RT-qPCR
(Additional file 1: Methods) and found that, when
Fig. 1 KRAS induces expression of AURKA and AURKB in lung cells. a Protein lysates of SALEB and SAKRAS cells were submitted to western blotting with
the indicated antibodies. b H1703-TrexB and H1703-G12V lung cancer cells were treated with 2 μg/mL doxycycline (DOX) for 24 h where indicated to
induce KRAS expression. Subsequently, protein lysates were prepared and submitted to western blotting with the indicated antibodies. TUBA) anti-α-
tubulin. c A549 and H358 stable cells with inducible expression of 2 different shRNAs targeting KRAS (shKR#1 and shKR#2) or a non-targeting shRNA (shCtrl)
were treated with 2 μg/mL doxycycline (DOX) for 5 days to induce shRNA expression where indicated. Protein lysates were prepared and submitted to
western blotting with the indicated antibodies
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compared to SALEB cells, SAKRAS cells have, not only a
higher expression of KRAS mRNA, but also a higher ex-
pression of AURKA and AURKB mRNAs (Additional file
2: Figure S1A). Therefore, these results show a correlation
between KRAS and Aurora kinase expression in primary
pulmonary cells.
In order to determine if KRAS can induce Aurora kinase
expression, we used both gain-of-function and loss-of-
function cell based models. For gain-of-function of KRAS,
we used HA-tagged KRASG12V-inducible H1703 human
lung cancer cells, that express oncogenic KRASG12V upon
doxycycline administration [41]. We observed that induc-
tion of KRASG12V expression with doxycycline in H1703
cells, as assessed by immunoblotting with an anti-HA tag
antibody, leads to increased AURKA and AURKB expres-
sion (Fig. 1b). These effects on Aurora kinase expression
were not observed in doxycycline-treated empty vector
control cells (H1703-TrexB cells), which do not express
KRASG12V (Fig. 1b). Similarly to what we observed in SAK-
RAS cells, induction of KRASG12V expression in H1703
cells leads to increased AURKA and AURKB mRNA levels
(Additional file 2: Figure S1B).
Next, we performed loss-of-function experiments
using KRAS mutant H358 and A549 cell lines with
doxycycline-inducible expression of shRNAs targeting
KRAS. shRNA expression upon doxycycline administra-
tion was monitored by fluorescence microscopy for the
red fluorescent reporter protein (Additional file 2: Figure
S1C). Consistent with our previous results, inhibition of
KRAS expression with two different shRNAs in both
A549 and H358 cell lines is accompanied by a decrease
in AURKA and AURKB expression (Fig. 1c). Again,
KRAS, AURKA and AURKB expression is unchanged in
A549 and H358 cells induced to express a non-targeting
shRNA (Fig. 1c). Finally, this decrease in AURKA and
AURKB protein levels is accompanied by a decrease in
mRNA levels (Additional file 2: Figure S1D). Taken to-
gether, these results confirm that, in lung cells, AURKA
and AURKB are KRAS targets, and strongly suggest that
KRAS signaling upregulates AURKA and AURKB tran-
scription or promotes AURKA and AURKB mRNA
stability.
Targeting Aurora A and Aurora B reduces the oncogenic
phenotype of KRAS-positive lung cancer cells
The above results, coupled to the fact the both AURKA
and AURKB have been implicated in promoting the ma-
lignant phenotype [20–25], led us to hypothesize that
AURKA and AURKB contribute to the oncogenic pheno-
type induced by KRAS. In order to test this hypothesis, we
assessed if simultaneous inhibition of AURKA and
AURKB activity with Aurora Kinase Inhibitor II (AI II), a
dual Aurora kinase pharmacological inhibitor, would
affect KRAS-positive lung cell oncogenicity.
Because AI II has higher affinity for AURKB [42, 43],
we decided to investigate first if AI II can effectively in-
hibit AURKA activity under the conditions used in our
experiments in order to validate dual inhibition of these
kinases. AURKA activity was assessed by the level of au-
tophosphorylation at threonine 288, which is required
for AURKA activity [44, 45]. As can be seen in Fig. 2a,
AI II inhibits AURKA autophosphorylation in a dose-
dependent manner.
Treatment of KRAS-positive cancer cell lines with AI
II effectively reduces, in a dose-dependent manner, cell
growth (Fig. 2b), as well as the ability to form colonies
under adherent conditions (Fig. 2c). This AI II-induced
loss of viability was corroborated by MTT reduction-
based assays, which show a similar dose-dependent
reduction of cell viability (Additional file 3: Figure S2A).
In both cell lines, AI II treatment resulted in an accu-
mulation of annexin V positive cells (Fig. 2d) and induced
caspase 3 cleavage (Additional file 3: Figure S2B). In
addition, AI II caused a reduction in the number of cells
in S phase and caused an accumulation of cells in the G2
phase of the cell cycle (Fig. 2e). These results indicate that
Aurora kinase inhibition in KRAS-positive cells not only
reduces cell proliferation, but also promotes apoptosis.
One important cell property that is associated with the
transformed phenotype is the ability of cells to grow in
an anchorage-independent manner. As can be seen in
Fig. 2f, AI II reduces, in a dose-dependent manner, the
ability of both cell lines to form colonies under non-
adherent conditions.
In order to determine the role of each individual Aurora
kinase in promoting KRAS-induced oncogenesis, we
performed loss-of-function experiments using KRAS
mutant H358 and A549 cell lines with doxycycline-
inducible expression of shRNAs targeting AURKA or
AURKB independently (Additional file 2: Figure S1C and
D). Consistent with our previous results, doxycycline
administration in both cell lines leads, not only to effective
inhibition of AURKA or AURKB expression with two dif-
ferent shRNAs each (Fig. 3a), but also to reduced growth
(Fig. 3b) and reduced ability to form colonies under adher-
ent conditions (Fig. 3c). Again, loss of viability was con-
firmed by MTT reduction-based assays (Additional file 3:
Figure S2C). As expected, these effects are not seen in
A549 and H358 cells induced to express a non-targeting
shRNA control upon doxycycline administration.
Similar to what we observed with AI II treatment,
shRNA-mediated knockdown of AURKA and AURKB
was accompanied by a reduction of the ability of these
cells to progress through the cell cycle, leading to accu-
mulation at G2 (Fig. 3d), as well as increased levels of
cleaved caspase 3 (Fig. 3e). Finally, AURKA or AURKB
knockdown in these cells also reduced anchorage-
independent growth (Fig. 3f ).
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Fig. 2 (See legend on next page.)
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These results indicate that AURKA and AURKB in-
hibition reduces proliferation and promotes apoptosis,
thereby leading to reduced growth and viability, as
well as reduces the ability of KRAS-positive lung can-
cer cells to maintain a transformed phenotype.
shRNA-mediated inhibition of Aurora A expression
reduces KRAS-induced tumor growth in vivo
In order to validate Aurora kinases as potential thera-
peutic targets for KRAS-induced lung cancer, it is import-
ant to demonstrate that Aurora kinase targeting reduces
KRAS-driven tumor growth in vivo. Given that the results
we obtained in vitro were similar for both AURKA and
AURKB targeting, and given that AURKA has been more
extensively implicated in promoting oncogenesis, we per-
formed in vivo studies with KRAS mutant A549 cells with
inducible inhibition of AURKA expression to evaluate the
effect of inhibition of AURKA expression for KRAS-
positive lung tumor xenograft growth.
For that purpose A549 cells with doxycycline-inducible
expression of a shRNA targeting AURKA (A549-shAKA)
or with doxycycline-inducible expression of a non-targeting
shRNA (A549-shCtrl) were inoculated subcutaneously in
nude mice. Doxycycline administration in mice inoculated
with A549-shAKA cells significantly reduced tumor growth
rate when compared to untreated mice inoculated with
these cells, as well as to doxycycline-treated and untreated
mice inoculated with A549-shCtrl cells (Fig. 4a). Consist-
ently, doxycycline-treated A549-shAKA tumors were
smaller (Fig. 4b), displayed reduced weight (Fig. 4c) and re-
duced AURKA expression (Fig. d). Nonetheless, AURKA
inhibition did not lead to tumor regression (Fig. 4a). This is
consistent with the fact that apoptotic cells were not de-
tected in these tumors (data not shown).
Inhibition of Aurora kinase activity reduces the oncogenic
properties of lung cells in a KRASG12V-dependent manner
In order to address if Aurora inhibition preferentially
affects KRAS-transformed cells, we used our previously
described cell-based models to assess the effects of
pharmacological inhibition of Aurora kinase activity in the
presence and absence of oncogenic KRAS expression.
As expected, SAKRAS cells grow faster than SALEB
cells (Fig. 5a, left panel) and form more colonies under
adherent conditions (Fig. 5b, left panel). Interestingly,
treatment with 1uM AI II reduces growth and colony
formation of SAKRAS cells without affecting the ability
of untransformed SALEB cells to grow (Fig. 5a, left
panel) and form colonies (Fig. 5b, left panel). In addition,
only SAKRAS cells are able to form colonies in soft agar,
a feature of transformed cells, and this ability is reduced
by AI II treatment (Fig. 5c, left panel).
Similarly, induction of KRASG12V expression by doxycyc-
line in H1703-G12V cells leads to enhanced growth (Fig. 5a,
right panel) and ability to form colonies both under adher-
ent (Fig. 5b, right panel) and non-adherent (Fig. 5c, right
panel) conditions. These increased abilities to grow and
form colonies were not observed in H1703 T-RexB cells
treated with doxycycline (Fig. 5a, b and c, middle panels),
which do not express oncogenic KRAS. Interestingly, treat-
ment with AI II abrogated the enhanced growth (Fig. 5a,
right panel), colony formation (Fig. 5b, right panel) and
anchorage-independent growth (Fig. 5c, right panel) of
H1703 G12V cells induced to express KRASG12V with
doxycycline, but had no effect in uninduced H1703 G12V
cells (Fig. 5a, b and c, right panels) or in H1703 T-RexB
cells (Fig. 5a, b and c, middle panels). Again, loss of viability
was confirmed by MTT reduction-based assays, whereby
MTT reduction is decreased upon treatment with AI II
only in cells expressing mutant KRASG12V (Additional file
4: Figure S3A and B). Interestingly, as assessed by caspase 3
cleavage (Additional file 4: Figure S3C), or by Annexin V/
PI staining (Additional file 4: Figure S3D), aurora kinase
targeting with AI II preferentially increases apoptosis of
KRASG12V-expressing H1703 cells.
These results show that Aurora inhibition primarily
exerts anti-tumor effects in the presence of oncogenic
KRASG12V, having little or no effect on normal cells or
tumorigenic cells without KRAS mutations. This sug-
gests that Aurora kinase inhibition therapy can preferen-
tially target KRASG12V transformed cells.
(See figure on previous page.)
Fig. 2 Dual pharmacological inhibition of AURKA and AURKB decreases the transformed phenotype of KRAS-positive lung cells. a A549 and H358 cells were
treated with 0.1 % DMSO or increasing concentrations of AI II as indicated for 72 h and protein lysates were prepared and submitted to Western blotting with
the indicated antibodies. b Growth curve analysis of A549 and H358 cells treated with the indicated concentrations of AI II compared to control-treated cells
(0.1 % DMSO) for the indicated times. c A549 and H358 cells were plated for clonogenic assays as described in methods and treated for 21 days with either
0.1 % DMSO or different concentrations of AI II as indicated. Colonies formed were stained with crystal violet and counted. Images shown are representative
of three independent experiments. d A549 and H358 cells were treated with 0.1 % DMSO or increasing concentrations of AI II as indicated for 72 h, stained
for Annexin V and propidium iodide (PI) as described in methods and Annexin V positive cells were analyzed by flow cytometry. e A549 and H358 cells were
treated with 0.1 % DMSO or increasing concentrations of AI II as indicated for 72 h, cells were stained with BrdU and PI as described in methods, and cell
cycle analysis was performed by flow cytometry. f Anchorage-independent growth was evaluated by plating A549 and H358 in soft agar as described in
methods. Cells were then treated for 21 days with either 0.1 % DMSO or different concentrations of AI II as indicated. Colonies formed were stained with MTT
and counted. Images shown are representative of three independent experiments. In all cases, statistical significance was determined when appropriate by
Student’s t-test (*p< 0.05, **p< 0.01) by comparing AI II-treated vs. DMSO-treated samples. Error bars represent average ± 1 s.d
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Fig. 3 (See legend on next page.)
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Discussion
In spite of recent studies that provide new promising strat-
egies for targeting KRAS directly [1–4], effective therapies
for KRAS-induced malignancies, including KRAS-induced
lung cancer, are still unavailable. Targeting KRAS indirectly
through its downstream effectors is also complicated by the
number and crosstalk of pathways regulated by KRAS that
contribute to the malignant phenotype [46, 47]. Effective
indirect KRAS targeting is likely to rely on combined inhib-
ition of critical targets, which may vary according to con-
text. Therefore, a better understanding of the molecular
pathways triggered by oncogenic KRAS in lung cancer is
warranted, as it can identify new potential targets to be
explored therapeutically.
In this work we demonstrated that AURKA and AURKB
are potential new promising targets for KRAS-induced
lung cancer therapy. Using three different cell-based
models, we have shown that oncogenic KRAS positively
regulates expression of AURKA and AURKB likely by
regulating AURKA and AURKB transcription or mRNA
stability (Fig. 1 and Additional file 2: Figure S1). An in-
crease in Aurora A expression was also observed in a
mouse model of malignant peripheral nerve sheath tumor
caused by overexpression of HRASG12V [37]. These results
are consistent with the fact that RAS activation leads to
phosphorylation and stabilization of the MYC transcrip-
tion factor [48], which in turn binds to the AURKA and
AURKB promoters and positively regulates their tran-
scription [49]. These results are also supported by the ob-
servation that AURKA and AURKB are required for in
vivo maintenance of MYC-induced tumors [49, 50].
Nevertheless, we cannot rule out that other mechanisms,
both transcriptional and post-transcriptional, may be in-
volved in the regulation of KRAS-induced AURKA and
AURKB activity. Recently, Bowman et al. [51] reported that
KRAS can induce phosphorylation of FADD by CK1α, and
that phosphorylated FADD is, not only required for KRAS-
induced lung tumorigenesis, but also that it interacts with
AURKA. In addition, Yang et al. [28] demonstrated that, in
ovarian cancer cells, oncogenic HRAS led to accumulation
of AURKA protein possibly via inhibition of AURKA prote-
olysis. Interestingly, AURKA and AURKB expression levels
have been used as diagnostic and prognostic markers in
lung cancer [16–19, 52], suggesting that these kinases play
a role in lung oncogenesis.
In order to investigate if AURKA and AURKB contribute
to the malignant phenotype induced by KRAS activation,
we either targeted AURKA or AURKB expression by RNA
interference or targeted their activity with a dual pharmaco-
logical inhibitor. By these approaches, we have shown that
these kinases are important for growth and viability of
KRAS-positive lung cancer cells (Figs. 2b–c and 3b–c).
These results are consistent with other studies showing that
these kinases are important for cancer cell growth, viability
and in vivo tumorigenicity [37, 53–56]. Nonetheless, our
findings demonstrate that these kinases also support the
malignant phenotype of KRAS-transformed lung cancer
cells.
We have determined that Aurora kinase targeting in
KRAS-positive lung cancer cells leads to loss of viability
through promoting cell cycle arrest at G2 and through
activation of apoptosis (Figs. 2d–e and 3d–e). This is
consistent with the fact that AURKA and AURKB are
master regulators of mitosis [10, 11], and that Aurora
kinase inhibition is known to promote cell cycle arrest
and apoptosis [14, 15].
More importantly, Aurora kinase targeting reduced
anchorage-independent growth of KRAS-transformed
lung cells (Figs. 2f, 3f and 5c), and inducible inhibition of
AURKA expression by RNA interference reduced A549
xenograft tumor growth in vivo (Fig. 4). Different studies
have shown that Aurora targeting reduces cell transform-
ation in vitro and tumorigenicity in vivo [50, 53–63], even
though these studies did not evaluate Aurora kinase
targeting in KRAS-driven oncogenesis. Different mecha-
nisms have been proposed to explain the role these
kinases play in promoting malignant transformation. One
possible mechanism would be through phosphorylation of
(See figure on previous page.)
Fig. 3 shRNA-mediated knockdown of AURKA or AURKB decreases the transformed phenotype of KRAS-positive lung cells. Unless otherwise indicated,
A549 and H358 stable cells with inducible expression of 2 different shRNAs targeting AURKA (shAKA#1 and shAKA#2), AURKB (shAKB#1 and shAKB#2) or
a non-targeting shRNA (shCtrl) were either treated with 2 μg/mL doxycycline (DOX) for 5 days to induce shRNA expression or left untreated (MOCK).
a Protein lysates of doxycycline-treated (+) and untreated (−) cells were submitted to western blotting with the indicated antibodies. TUBA) anti-α-tubulin.
b Growth curve analysis of the indicated cells. All cells were treated with 2 μg/mL doxycycline (DOX) for the indicated times. c The indicated cells were
plated for clonogenic assays as described in methods and treated for 21 days with 2 μg/mL doxycycline (DOX). Colonies formed were stained with crystal
violet and counted. Images shown are representative of three independent experiments. d The indicated treated (DOX) or untreated (MOCK) cells were
stained with BrdU and propidium iodide (PI) as described in methods, and cell cycle analysis was performed by flow cytometry. e Protein lysates of A549
and H358 stable cells with inducible expression of 2 different shRNAs targeting AURKA (shAKA#1 and #2), AURKB (shAKB#1 and #2) or a non-targeting
shRNA (shCtrl), treated (+) or not (-) with 2 μg/mL doxycycline (DOX) for 5 days, were submitted to western blotting with the indicated antibodies. C3)
anti-caspase 3. f Anchorage-independent growth was evaluated by plating the indicated cells in soft agar as described in methods. Cells were
then treated for 21 days with 2 μg/mL doxycycline (DOX) or left untreated (MOCK). Colonies formed were stained with MTT and counted.
Images shown are representative of three independent experiments. In all cases, statistical significance was determined when appropriate by
Student’s t-test (*p < 0.05, **p < 0.01) and the groups being compared are indicated by horizontal bars
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LIMK2 by AURKA [64]. Another possibility is that
AURKA can promote RAS farnesylation, thus increasing
the ability of this oncoprotein to transmit signals to down-
stream effectors [28]. In the case of AURKB, phosphoryl-
ation of CDCA8 by AURKB can play a role in promoting
cell growth, survival and xenograft tumor growth [25]. Fi-
nally, both kinases have been proposed to mediate the
oncogenic effects of MYC [49], an oncogenic transcription
factor known to be positively regulated by RAS [48].
Interestingly, whereas AURKA targeting in vitro
caused cells to undergo apoptosis (Figs. 2d and 3e and
Additional file 3: Figure S2B, Additional file 4: Figure
S3C and D), we failed to detect apoptotic cells in xeno-
graft tumors with RNAi-mediated inihibition of AURKA
expression (data not shown). This discrepancy between
our in vitro and in vivo data could reflect the fact that
tumor extrinsic survival factors influenced by the micro-
environment in vivo can affect the ability of tumors cells
to undergo cell death upon inhibition of oncogenic path-
ways. It is known that several key stages in apoptosis are
sensitive to depletion of cellular energy reserves, which
results from conditions, such as hypoxia and low glu-
cose, which are found in vivo [65]. In addition, hypoxia
is known to select cells that have lost their apoptotic
potential [66], so it is also likely that an initial apoptotic
response to AURKA inhibition might have occurred,
leading to expansion of apoptotic resistant cells and fail-
ure to detect apoptotic cells at the endpoint.
In order to validate Aurora kinases as therapeutic tar-
gets for KRAS-induced lung cancer, it is important to
show that inhibiting these kinases preferentially targets
lung cancer cells expressing oncogenic KRAS. In order to
Fig. 4 shRNA-mediated knockdown of AURKA reduces xenograft
tumor growth. a A549 stable cells with inducible expression of a
shRNA targeting AURKA (shAKA) or a non-targeting shRNA (shCtrl)
were injected subcutaneously in nude mice (n = 9 per group). shRNA
expression was induced by doxycycline (DOX) administration in the
drinking water as described in methods (n= 5 per group). Alternatively,
mice were left untreated (MOCK) to control for doxycycline-mediated
effects (n= 4 per group). The graph shows tumor volume measurements,
which were initiated 26 days after inoculation (day 0). Error bars
represent average ± 1 s.d. b Representative images of the tumors
at day 56 after inoculation. c A549 stable cells with inducible
expression of a shRNA targeting AURKA (shAKA) or a non-targeting
shRNA (shCtrl) were injected subcutaneously in nude mice (n = 12
per group). shRNA expression was induced by doxycycline (DOX)
administration in the drinking water as described in methods
(n = 6 per group). Tumor weights at day 56. Error bars represent
average ± 1 s.d. In all cases, statistical significance was determined
when appropriate by one-way analysis of variance (ANOVA) followed
by Bonferroni’s multiple comparison test (a) or by Student's t-test (c)
(*p < 0.05) and the significantly different comparisons are indicated by
vertical (a) or horizontal (c) bars. d Protein lysates of xenograft tumors
were submitted to western blotting with the indicated antibodies.
ACTB) anti-β-actin
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Fig. 5 (See legend on next page.)
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evaluate the specificity of the biological effects caused by
Aurora kinase targeting, we used the dual AURKA and
AURKB inhibitor AI II to treat lung cell pairs, that only
differed by their expression of oncogenic KRASG12V. Our
results show, for the first time, that AURKA and AURKB
inhibition reduces growth, viability and anchorage- inde-
pendent growth in a KRAS-dependent manner (Fig. 5 and
Additional file 4: Figure S3).
Our results support a model, whereby oncogenic
KRAS effector pathways trigger abnormally high levels
of AURKA and AURKB activation, rendering KRAS-
transformed cells more sensitive than other cells to Aur-
ora kinase targeting. These results are important, not
only because they identify a specific vulnerability of
KRAS-transformed lung cells, but also because this vul-
nerability can be used to develop targeted therapies for
KRAS-induced lung cancer. The potential for clinical
translation is further underscored by the fact that differ-
ent Aurora kinase inhibitors, including alisertib and
danusertib are undergoing phase II/III clinical trials for
different malignancies [15, 59, 67, 68], even though very
few combination trials using these drugs are currently
ongoing.
Taken together, our results provide strong evidence
that Aurora kinases are KRAS downstream effectors that
play an important role in promoting the oncogenic
phenotype, and suggest AURKA and/or AURKB inhib-
ition as a promising approach to be explored alone or
preferentially in combination with other strategies for
KRAS-induced lung cancer therapy.
Conclusions
In conclusion, our results show that AURKA and
AURKB are not only regulated by KRAS, but also pro-
mote KRAS-induced oncogenesis. Furthermore, target-
ing Aurora kinases by RNA interference reduces the
oncogenic phenotype of KRAS mutant lung cancer cells
in vitro and AURKA targeting slows tumor growth in
vivo. Finally, Aurora kinase pharmacological inhibition
preferentially targets lung cancer cells expressing
KRASG12V, thereby supporting our hypothesis that
AURKA and AURKB are promising targets for KRAS-
induced lung cancer therapy.
Methods
Cell lines, antibodies and reagents
A549 (ATCC CCL-185) and H358 (ATCC CRL-5807) cells
were cultivated in RPMI-1640 medium (ATCC 30–2001)
supplemented with 10 % (vol/vol) fetal bovine serum (FBS),
without antibiotics. HEK 293 T/17 cells (ATCC CRL-
11268) were cultivated in Dulbecco’s Modified Eagle’s
Medium (DMEM) supplemented with 10 % (vol/vol) FBS,
without antibiotics. H1703 (ATCC CRL-5889) genetically
modified to inducibly express KRASG12V or empty vector
control (T-RexB) [40] were cultivated in RPMI-1640
medium supplemented with 10 % (vol/vol) FBS, 10 μg/mL
blasticidin (#A1113903, Invitrogen) and 3 μg/mL zeocin
(#R25001, Invitrogen). 2 μg/mL doxycycline (#D3447,
Sigma Aldrich) was added to the medium to induce
KRASG12V expression when appropriate (see figure leg-
ends). SALEB and SAKRAS cells [39] were a kind gift from
Dr. Scott Randell, UNC School of Medicine. They were cul-
tured in supplemented Bronchial Epithelial Cell Growth
Medium (BEGM, Lonza). The antibodies used were as fol-
lows: Anti-AURKA (#4718, Cell Signaling Technology),
anti-pAURKA (#3079, Cell Signaling Technology), anti-
AURKB (#3094, Cell Signaling Technology), anti-GAPDH
(#25778, Santa Cruz Biotechnology), anti-HA-tag (#H3663,
Sigma-Aldrich), anti-PanRAS (#OP40, Merck Millipore),
anti-cleaved caspase 3 (#9661, Cell Signalling), anti-full cas-
pase 3 (#9662, Cell Signalling), anti-β-actin (#7210, Santa
Cruz Biotechnology) and anti-α-tubulin (#T9026, Sigma-
Aldrich). Secondary antibodies were as follows: anti-rabbit
Alexa Fluor® 680 (#A-21109 Life Technologies), anti-mouse
Alexa Fluor® 680 (#A-21058 Life Technologies), anti-rabbit
IRDye® 800CW (#926-32211, Li-Cor) and anti-mouse
IRDye® 800CW (#926-32210, Li-Cor). Cells were treated as
described in figures with Aurora Inhibitor II (AI II,
#189404, Merck Millipore), which is a dual Aurora A and
Aurora B inhibitor.
Generation of lung cells with inducible inhibition of KRAS,
Aurora A or Aurora B expression by RNA interference
Lentiviral particles were produced in HEK 293 T/17 cells
by co-transfection of lentiviral packaging plasmids
pCMV-VSVG and pCMV-dR8.2 dvpr (Addgene) with
pTRIPZ lentiviral vectors (GE Dharmacon) expressing
(See figure on previous page.)
Fig. 5 AURKA or AURKB targeting decreases the transformed phenotype of lung cells in a KRAS-dependent manner. Primary immortalized human
airway cells (SALEB) and their KRAS-transformed counterpart (SAKRAS) were treated with 0.1 % DMSO (DMSO) or 1uM AI II (AI II) as indicated.
H1703-TrexB and H1703-G12V lung cancer cells were also treated with 0.1 % DMSO (DMSO) or 1 μM AI II (AI II) as indicated. To induce KRAS
expression H1703-TrexB and H1703-G12V cells were simultaneously treated with 2 μg/mL doxycycline (DOX + DMSO or DOX + AI II) where
indicated. a Growth curve analysis of cells. All drug treatments (DMSO, AI II, DOX + DMSO, DOX + AI II) were continued for 12 days. b Cells
were plated for clonogenic assays as described in methods and treated for 21 days as indicated. Colonies formed were stained with crystal
violet and counted. Images shown are representative of three independent experiments. c Anchorage-independent growth was evaluated
by plating the indicated cells in soft agar as described in methods. Cells were then treated for 21 days as indicated. Colonies formed were
stained with MTT and counted. Images shown are representative of three independent experiments. In all cases, statistical significance was
determined when appropriate by Student’s t-test (*p < 0.05, **p < 0.01) and the groups being compared are indicated by horizontal bars
dos Santos et al. Molecular Cancer  (2016) 15:12 Page 10 of 14
the desired shRNAs according to the manufacturer’s
protocol. The following pTRIPZ lentiviral vectors were
used: a lentiviral vector expressing a non-targeting con-
trol shRNA (shCtrl, RHS 4743), two lentiviral vectors
expressing different shRNAs targeting KRAS (shKR#1,
V3THS_314004 and shKR#2, V3THS_314009), two
lentiviral vectors expressing different shRNAs targeting
Aurora A (shAKA#1, V2THS_12364 and shAKA#2,
V2THS_153609) and two lentiviral vectors expressing
different shRNAs targeting Aurora B (shAKB#1,
V2THS_28606 and shAKB#2, V2THS_28601). In each
case, A549 and H358 cells were infected with 1 MOI of
lentiviral particles and selected with 2 μg/mL puromycin
(#A1113803, Life Technologies) for two weeks. Individ-
ual cell clones were induced with 2 μg/mL doxycycline
(#D9891, Sigma-Aldrich) for 5 days and screened for
expression of the reporter red fluorescent protein (tur-
boRFP), as well as for inhibition of expression of shRNA
targets. Cells with at least 80 % knockdown levels were
used to perform all biological assays.
Growth curve analysis
Cells were seeded at a confluence of 5 × 103 cells per
well in 6-well adherent plates and allowed to proliferate
for 12 days with medium changed daily. Cells were
counted every two 2 days. Trypan blue (#T8154, Sigma-
Aldrich) was used to exclude dead cells. All conditions
were done in triplicate.
Clonogenic assay
Cells were seeded at 500 cells per plate in 60 mm adherent
plates in triplicate. Cells were allowed to form colonies for
2 weeks with medium changed daily. Colonies were
stained with crystal violet solution and counted manually.
Soft agar assay
1 × 103 cells were ressuspended in cell culture medium
containing 0.3 % low-melting-point agarose and were
plated onto a solidified bottom layer medium containing
0.6 % agarose in 24-well plates. Liquid medium was
added after 24 h and changed every three days. Colonies
were allowed to grow for 3 weeks and subsequently
stained with 1 mg/mL 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT, #M5655, Sigma-
Aldrich) for 2 h and colonies were counted. All condi-
tions were done in sextuplicate.
Western blotting
1 × 105 cells were grown in 60 mm plates and whole cell ly-
sates were isolated using RIPA buffer (20 mM Tris–HCl
pH 7.5, 150 mM NaCl, 1 mM Na2EDTA, 1 mM EGTA,
1 % NP-40) supplemented with protease and phosphatase
inhibitors (1 μg/mL leupeptin, 1 % sodium deoxycholate,
2.5 mM sodium pyrophosphate, 1 mM b-glycerophosphate,
1 mM Na3VO4). 25 μg of protein/lane were electropho-
resed in 10 or 12 % polyacrylamide minigels at 120 V for
90 min and transferred to nitrocellulose membranes. After
blocking, the membranes were incubated with primary
antibody, followed by incubation with fluorescently labelled
secondary antibodies. Fluorescence detection was per-
formed using ODYSSEY® CLx (Li-Cor®).
AURKA phosphorylation assay
1 × 105 cells were grown in 60 mm plates and treated
with Aurora inhibitor II (#189404, Merck Millipore) for
72 h. 24 h after cell seeding, 2 mM thymidine (#T1895,
Sigma- Aldrich) was added. The thymidine block was re-
leased after 24 h of incubation and cells were cultured
for an additional 8 h. Finally, 100 ng/mL nocodazole
(#M1404, Sigma-Aldrich) was added for 16 h. Cells were
harvested and whole lysates were analyzed by Western
blotting to check for AURKA phosphorylation.
Cell cycle analysis
Cells were seeded at a confluence of 1 × 105 cells in 6-well
adherent plates. After drug treatment or doxycycline-
mediated expression of shRNAs, cells were incubated with
50 μM 5-Bromo-2′-deoxyuridine (BrdU, #19-160, Merck
Millipore) in the dark for 2 h, and fixed in 70 % ethanol.
Cells were treated with 100 μg/mL RNase A (#EN0531,
Thermo Fisher Scientific) for 30 min at 37 °C followed by
2 M HCl for 20 min at room temperature. Suspended cells
were incubated in 100 μL of Alexa Fluor® 488-labeled
BrdU antibody (#FCMAB101A4, Merck Millipore) for 1 h
in the dark, and finally resuspended in a buffer containing
100 μg/mL of propidium iodide (#81845, Sigma-Aldrich)
for analysis using flow cytometry in a BD FACSVerse™
Flow Cytometer (BD Biosciences). Results were analyzed
with Kaluza® Flow Analysis Software (Beckman Coulter).
Annexin V/PI staining
Cells were seeded at a confluence of 1 × 106 cells in
100 mm adherent plates and treated with different con-
centrations of AI-II or doxycycline as indicated in the
figure legends. Cells were stained with Annexin V and
propidium iodide (PI) according to the Annexin V-FITC
Kit (#130-092-052, Miltenyi Biotec) instructions. Briefly,
cells were resuspended in binding buffer, incubated with
FITC-labeled Annexin V antibody for 15 min, followed
by incubation in binding buffer containing 100 μg/mL
propidium iodide (PI). Cells were then analyzed by flow
cytometry in a BD FACSVerse™ Flow Cytometer (BD
Biosciences). Results were analyzed with Kaluza® Flow
Analysis Software (Beckman Coulter).
Xenograft tumor growth analysis
2 × 106 A549 cells with doxycycline-inducible expression
of a shRNA targeting AURKA (A549-shAKA) or with
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doxycycline-inducible expression of a non-targeting
shRNA (A549-shCtrl) were subcutaneously inoculated
into the flanks of 8-week-old, male Balb/C nude mice in
pathogen-free conditions according to the protocols ap-
proved by the Institutional Animal Care and Use Com-
mittee of the University of São Paulo Chemistry Institute
Animal Facility. Animals were monitored every 3 days,
and, once primary tumors were palpable (26 days after
inoculation), 1 mg/mL doxycycline was added to the
drinking water to induce shRNA expression. Tumor vol-
umes were determined by direct diameter measurement
with calipers followed by the following calculation: (large
diameter) x (small diameter)2/2. Animals were sacrificed
by CO2 euthanasia 56 days after inoculation, and tumor
weight was determined. Statistical significance of differ-
ences observed in tumor growth and weight was deter-
mined by one-way analysis of variance (ANOVA)
followed by Bonferroni’s multiple comparison test or by
the Student's t-test.
Statistics
All values are presented either as mean ± 1SD or as rep-
resentative images of at least three independent experi-
ments. Data analysis was performed using the statistical
software Prism 5 (GraphPad Software, Inc., San Diego,
CA, USA). Differences between groups were evaluated
by one-way analysis of variance (ANOVA) followed by
Bonferroni’s multiple comparison test or alternatively by
the Student's t-test. Differences were considered statisti-
cally significant at p < 0.05.
Additional files
Additional file 1: Materials and methods used in the data
presented in the additional figures, which are not included in the
main manuscript. (PDF 80 kb)
Additional file 2: Figure S1. KRAS regulates AURKA and AURKB mRNA
levels. a Expression of KRAS, AURKA, and AURKB was analyzed by real-time
quantitative PCR in immortalized primary epithelial lung cells (SALEB) and
their isogenic KRAS-transformed counterpart (SAKRAS), showing that
KRAS mRNA expression positively correlates with both AURKA and
AURKB mRNA expression. Statistical significance was measured by Student’s
t-test (*p < 0.05) and error bars represent average ± 1s.d. b mRNA expression
of KRAS, AURKA, and AURKB was analyzed by real-time quantitative PCR in
H1703 lung cancer cells engineered to express KRASG12V inducibly (G12V) in
comparison to empty vector-transfected H1703 cells (TrexB). To induce KRAS
expression, cells were treated with 2 μg/mL doxycycline for the indicated
times. Statistical significance was measured by Student’s t-test (*p < 0.05) by
comparing treated samples (DOX) to untreated control samples (MOCK).
Error bars represent average ± 1s.d. c Fluorescence microscopy images of
A549 and H358 stable cells with inducible expression of 2 different shRNAs
targeting KRAS (shKR#1 and shKR#2), AURKA (shAKA#1 and shAKA#2),
AURKB (shAKB#1 and shAKB#2) or a non-targeting shRNA (shCtrl) showing
induction of red fluorescent reporter protein (RFP) expression upon
treatment with 2 μg/mL doxycycline for 5 days (DOX) when compared to
untreated (MOCK) cells. Brightfield images of the same fields are included
for comparison. d mRNA expression of KRAS, AURKA, and AURKB was analyzed
by real-time quantitative PCR in A549 and H358 stable cells with inducible
expression of 2 different shRNAs targeting KRAS (shKR#1 and shKR#2) or a
non-targeting shRNA (shCtrl). Cells were either treated with 2 μg/mL
doxycycline (DOX) for 5 days to induce shRNA expression or left untreated
(MOCK). Statistical significance was measured by Student’s t-test (*p< 0.05,
**p< 0.01) by comparing treated samples (DOX) to untreated control samples
(MOCK). Error bars represent average ± 1s.d. (PDF 648 kb)
Additional file 3: Figure S2. Pharmacological or shRNA-mediated
inhibition of AURKA and/or AURKB leads to decreased cell viability
and induces apoptosis. a A549 and H358 cells were treated with
0.1 % DMSO or 1uM AI II for 72h. Cell viability was measured using a
colorimetric MTT assay (described in the Additional file 1: Methods).
b Protein lysates of A549 and H358 cells treated with 0.1 % DMSO or
the indicated concentrations of AI II for 72h were submitted to
western blotting with the indicated antibodies. C3) anti-caspase 3;
ACTB) anti-β-actin. c A549 and H358 stable cells with inducible
expression of 2 different shRNAs targeting AURKA (shAKA#1 and #2),
AURKB (shAKB#1 and #2) or a non-targeting shRNA (shCtrl) were
treated with 2 μg/mL doxycycline (DOX) for 5 days to induce shRNA
expression. Cell viability of doxycycline-treated cells was compared to
untreated cells using a colorimetric MTT assay (described in the
Additional file 1: Methods). Statistical significance in all cases was
measured by Student’s t-test (**p < 0.01, ***p < 0.0001) when
compared to experimental control samples (MOCK-treated cells).
Error bars represent average ± 1s.d. (PDF 263 kb)
Additional file 4: Figure S3. Aurora inhibition reduces viability and
induces cell death in a KRAS-dependent manner. a Primary immortalized
human airway cells (SALEB) and their KRAS-transformed counterpart (SAK-
RAS) were treated with 0.1 % DMSO or 1uM AI II. Cell viability was measured
at 72h using a colorimetric MTT assay (described in the Additional file 1:
Methods). Statistical significance was determined by Student’s t-test (*p <
0.05) when compared to experimental control samples (DMSO-treated cells).
Error bars represent average ± 1s.d. b, c and d H1703-TrexB and H1703-
G12V lung cancer cells were treated with 0.1 % DMSO (DMSO) or 1μM AI II
(AI II) as indicated for 72h. To induce KRAS expression H1703-TrexB and
H1703-G12V cells were simultaneously treated with 2μg/mL doxycycline
(DOX + DMSO or DOX + AI II) where indicated. b Cell viability was measured
using a colorimetric MTT assay (described in the Additional file 1: Methods).
Statistical significance was determined by Student’s t-test (*p < 0.05, ***p <
0.0001) when compared to experimental control samples (DMSO-treated
cells). Error bars represent average ± 1s.d. c Protein lysates were submitted
to western blotting with the indicated antibodies. C3) anti-caspase 3. d
Annexin V positive cells were analyzed by flow cytometry. (PDF 455 kb)
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